The Packer family’s Ellerston Capital has become a substantial shareholder in Acrux, taking a 5.4% stake in the biotechnology company. Ac…
The Packer family’s Ellerston Capital has become a substantial shareholder in Acrux, taking a 5.4% stake in the biotechnology company. Ac…
Let’s finish the week with one of the best news story to come out of the Australian biotechnology for years. This week Melbourne-based …
The collapses keep coming at the small end of Australia’s business community – companies from a range of sectors (including advertising, t…
After a difficult 18 months for the Australian biotechnology sector, Melbourne-based drug developer Acrux has boosted the industry’s confide…
Struggling Melbourne anti-HIV drug developer Narhex Life Sciences has been placed in administration after a long battle for survival, three …
Australian biotech company Acrux has announced plans to export its new testosterone treatment across the globe, following a trial which show…
